Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Fly Intel: After-Hours Movers » 18:59
07/08/20
07/08
18:59
07/08/20
18:59
EXFO

EXFO Inc.

$3.24 /

+0.1 (+3.18%)

, SAR

Saratoga Investment

$15.61 /

+0.475 (+3.14%)

, ACER

Acer Therapeutics

$3.21 /

+0.07 (+2.23%)

, OPTN

Optinose

$4.26 /

-0.28 (-6.17%)

, ANAB

AnaptysBio

$22.71 /

+0.05 (+0.22%)

, VERI

Veritone

$12.11 /

-0.26 (-2.10%)

, PTC

PTC

$78.36 /

+1.76 (+2.30%)

, SAP

SAP

$146.75 /

+2.75 (+1.91%)

, CRNX

Crinetics

$16.46 /

-0.62 (-3.63%)

, FTCH

Farfetch

$19.59 /

+1.4 (+7.70%)

, COST

Costco

$316.38 /

+0.095 (+0.03%)

, REGN

Regeneron

$639.69 /

-0.92 (-0.14%)

, BBBY

Bed Bath & Beyond

$10.40 /

+0.15 (+1.46%)

, OTIC

Otonomy

$3.58 /

+0.01 (+0.28%)

, GLG

TD Holdings

$2.44 /

+0.06 (+2.52%)

, TPB

Turning Point Brands

$26.50 /

+1.945 (+7.92%)

, FIVE

Five Below

$103.28 /

+4.72 (+4.79%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
VERI Veritone
$12.11 /

-0.26 (-2.10%)

TPB Turning Point Brands
$26.50 /

+1.945 (+7.92%)

SAR Saratoga Investment
$15.61 /

+0.475 (+3.14%)

SAP SAP
$146.75 /

+2.75 (+1.91%)

REGN Regeneron
$639.69 /

-0.92 (-0.14%)

PTC PTC
$78.36 /

+1.76 (+2.30%)

OTIC Otonomy
$3.58 /

+0.01 (+0.28%)

OPTN Optinose
$4.26 /

-0.28 (-6.17%)

GLG TD Holdings
$2.44 /

+0.06 (+2.52%)

FTCH Farfetch
$19.59 /

+1.4 (+7.70%)

FIVE Five Below
$103.28 /

+4.72 (+4.79%)

EXFO EXFO Inc.
$3.24 /

+0.1 (+3.18%)

CRNX Crinetics
$16.46 /

-0.62 (-3.63%)

COST Costco
$316.38 /

+0.095 (+0.03%)

BBBY Bed Bath & Beyond
$10.40 /

+0.15 (+1.46%)

ANAB AnaptysBio
$22.71 /

+0.05 (+0.22%)

ACER Acer Therapeutics
$3.21 /

+0.07 (+2.23%)

EXFO EXFO Inc.
$3.24 /

+0.1 (+3.18%)

SAR Saratoga Investment
$15.61 /

+0.475 (+3.14%)

01/13/20 Ladenburg
Saratoga Investment upgraded to Buy from Neutral at Ladenburg
01/09/20 Compass Point
Saratoga Investment upgraded to Buy from Neutral at Compass Point
12/19/19 National Securities
Saratoga Investment initiated with a Neutral at National Securities
08/29/19 Aegis
Saratoga Investment initiated with a Buy at Aegis
ACER Acer Therapeutics
$3.21 /

+0.07 (+2.23%)

OPTN Optinose
$4.26 /

-0.28 (-6.17%)

06/30/20 Cantor Fitzgerald
OptiNose anti-COVID-19 candidate could provide 'significant upside, says Cantor
02/07/20 Piper Sandler
Piper Sandler views Optinose risk/reward as attractive after allergist survery
12/18/19 Cowen
Optinose initiated with an Outperform at Cowen
10/01/19 Jefferies
Optinose risk/reward looks increasingly attractive, says Jefferies
ANAB AnaptysBio
$22.71 /

+0.05 (+0.22%)

01/16/20 Cantor Fitzgerald
AnaptysBio risk/reward favorable into second half data, says Cantor Fitzgerald
11/11/19 SunTrust
AnaptysBio downgraded to Hold from Buy at SunTrust
11/08/19 Cantor Fitzgerald
Cantor cuts AnaptysBio target to $28 from $140, sees value in shares
11/08/19 Jefferies
AnaptysBio downgraded to Hold from Buy at Jefferies
VERI Veritone
$12.11 /

-0.26 (-2.10%)

07/06/20 Craig-Hallum
Craig-Hallum says sell Veritone after stock surpasses 'reasonable' valuation
07/06/20 Craig-Hallum
Veritone downgraded to Sell from Hold at Craig-Hallum
06/25/20 Roth Capital
Veritone price target raised to $18 from $7 at Roth Capital
11/08/19 JMP Securities
Veritone price target lowered to $7 from $10 at JMP Securities
PTC PTC
$78.36 /

+1.76 (+2.30%)

06/11/20 Rosenblatt
PTC's highly recurring revenue model underappreciated, says Rosenblatt
06/11/20 Wedbush
PTC price target raised to $78 from $70 at Wedbush
06/10/20 Mizuho
PTC price target raised to $95 from $80 at Mizuho
06/05/20 Needham
PTC initiated with a Buy at Needham
SAP SAP
$146.75 /

+2.75 (+1.91%)

07/08/20 UBS
SAP price target raised to EUR 142 from EUR 118 at UBS
06/16/20 Oppenheimer
SAP price target raised to $137 from $115 at Oppenheimer
06/16/20 RBC Capital
SAP price target raised to $142 from $117 at RBC Capital
06/15/20 Jefferies
SAP price target raised to $149 from $145 at Jefferies
CRNX Crinetics
$16.46 /

-0.62 (-3.63%)

05/11/20 Cantor Fitzgerald
Crinetics price target raised to $38 from $28 at Cantor Fitzgerald
05/08/20 Piper Sandler
Piper Sandler continues to recommend Crinetics after paltusotine data
04/07/20 Piper Sandler
Crinetics shares 'should be up meaningfully,' says Piper Sandler
12/23/19 Roth Capital
Crinetics initiated with a Buy at Roth Capital
FTCH Farfetch
$19.59 /

+1.4 (+7.70%)

07/08/20 China Renaissance
Farfetch upgraded to Buy from Hold at China Renaissance
07/01/20 Deutsche Bank
Farfetch price target raised to $23 from $17 at Deutsche Bank
06/26/20 KeyBanc
Farfetch price target raised to $23 from $17 at KeyBanc
06/25/20 BTIG
Farfetch upgraded to Buy from Neutral at BTIG
COST Costco
$316.38 /

+0.095 (+0.03%)

05/29/20 Baird
Costco improved comps seen likely for May, says Baird
05/29/20 RBC Capital
Costco price target raised to $348 from $332 at RBC Capital
05/06/20 Baird
Costco SSS decline due to pressure from temporal factors, says Baird
04/15/20 Citi
Costco assumed with a Neutral at Citi
REGN Regeneron
$639.69 /

-0.92 (-0.14%)

07/08/20 SunTrust
Regeneron upgraded to Buy at SunTrust on Eylea resilience and pipeline
07/08/20 SunTrust
Regeneron upgraded to Buy from Hold at SunTrust
07/08/20 Canaccord
Regeneron price target raised to $700 from $660 at Canaccord
07/01/20 Oppenheimer
Regeneron price target raised to $675 from $625 at Oppenheimer
BBBY Bed Bath & Beyond
$10.40 /

+0.15 (+1.46%)

07/07/20 Raymond James
Bed Bath & Beyond price target raised to $13 from $9 at Raymond James
05/26/20 Odeon Capital
Bed Bath & Beyond upgraded to Buy from Hold at Odeon Capital
04/16/20 Loop Capital
Bed Bath & Beyond Q4 results 'less bad than feared' says Loop Capital
04/08/20 Loop Capital
Bed Bath & Beyond price target lowered to $5 from $12 at Loop Capital
OTIC Otonomy
$3.58 /

+0.01 (+0.28%)

07/07/20 Cantor Fitzgerald
Otonomy price target raised to $11 from $9 at Cantor Fitzgerald
07/07/20 H.C. Wainwright
Otonomy price target raised to $9 from $8 at H.C. Wainwright
06/15/20 Piper Sandler
Piper remains optimistic on Otonomy ahead of near-term clinical readouts
06/01/20 Oppenheimer
Otonomy assumed with an Outperform at Oppenheimer
GLG TD Holdings
$2.44 /

+0.06 (+2.52%)

TPB Turning Point Brands
$26.50 /

+1.945 (+7.92%)

07/08/20 Craig-Hallum
Turning Point Brands initiated with a Buy at Craig-Hallum
01/06/20 Buckingham
Vape plan looks better than expected for Turning Point, says Buckingham
11/26/19 Buckingham
Buckingham starts Turning Point at Buy, says 'far more than a vaping play'
11/26/19 Buckingham
Turning Point Brands initiated with a Buy at Buckingham
FIVE Five Below
$103.28 /

+4.72 (+4.79%)

06/10/20
Fly Intel: Top five analyst upgrades
06/10/20 JPMorgan
Five Below price target raised to $123 from $103 at JPMorgan
06/10/20 Jefferies
Five Below price target raised to $140 from $89 at Jefferies
06/10/20 Credit Suisse
Five Below price target raised to $116 from $93 at Credit Suisse
VERI Veritone
$12.11 /

-0.26 (-2.10%)

TPB Turning Point Brands
$26.50 /

+1.945 (+7.92%)

SAR Saratoga Investment
$15.61 /

+0.475 (+3.14%)

SAP SAP
$146.75 /

+2.75 (+1.91%)

REGN Regeneron
$639.69 /

-0.92 (-0.14%)

PTC PTC
$78.36 /

+1.76 (+2.30%)

OTIC Otonomy
$3.58 /

+0.01 (+0.28%)

OPTN Optinose
$4.26 /

-0.28 (-6.17%)

FTCH Farfetch
$19.59 /

+1.4 (+7.70%)

FIVE Five Below
$103.28 /

+4.72 (+4.79%)

EXFO EXFO Inc.
$3.24 /

+0.1 (+3.18%)

CRNX Crinetics
$16.46 /

-0.62 (-3.63%)

COST Costco
$316.38 /

+0.095 (+0.03%)

BBBY Bed Bath & Beyond
$10.40 /

+0.15 (+1.46%)

ANAB AnaptysBio
$22.71 /

+0.05 (+0.22%)

ACER Acer Therapeutics
$3.21 /

+0.07 (+2.23%)

  • 09
    Jul
  • 09
    Jul
  • 27
    May
  • 15
    Apr
  • 21
    Nov
SAP SAP
$146.75 /

+2.75 (+1.91%)

REGN Regeneron
$639.69 /

-0.92 (-0.14%)

COST Costco
$316.38 /

+0.095 (+0.03%)

BBBY Bed Bath & Beyond
$10.40 /

+0.15 (+1.46%)

SAR Saratoga Investment
$15.61 /

+0.475 (+3.14%)

SAP SAP
$146.75 /

+2.75 (+1.91%)

REGN Regeneron
$639.69 /

-0.92 (-0.14%)

OTIC Otonomy
$3.58 /

+0.01 (+0.28%)

FTCH Farfetch
$19.59 /

+1.4 (+7.70%)

FIVE Five Below
$103.28 /

+4.72 (+4.79%)

EXFO EXFO Inc.
$3.24 /

+0.1 (+3.18%)

COST Costco
$316.38 /

+0.095 (+0.03%)

BBBY Bed Bath & Beyond
$10.40 /

+0.15 (+1.46%)

ACER Acer Therapeutics
$3.21 /

+0.07 (+2.23%)

REGN Regeneron
$639.69 /

-0.92 (-0.14%)

FTCH Farfetch
$19.59 /

+1.4 (+7.70%)

FIVE Five Below
$103.28 /

+4.72 (+4.79%)

COST Costco
$316.38 /

+0.095 (+0.03%)

BBBY Bed Bath & Beyond
$10.40 /

+0.15 (+1.46%)

Hot Stocks
AnaptysBio gets orphan drug designation of imsidolimab for pustular psoriasis » 16:11
07/08/20
07/08
16:11
07/08/20
16:11
ANAB

AnaptysBio

$22.64 /

-0.02 (-0.09%)

AnaptysBio announced that…

AnaptysBio announced that the U.S. Food and Drug Administration has granted orphan drug designation for imsidolimab, the company's proprietary anti-interleukin-36 receptor, IL-36R, antibody, for the treatment of patients with GPP. The FDA's Office of Orphan Drug Products grants orphan status to support development of medicines for underserved patient populations, or rare disorders, that affect fewer than 200,000 people in the U.S. Orphan drug designation may provide certain benefits to AnaptysBio, including market exclusivity upon regulatory approval, if received, exemption of FDA application fees and tax credits for qualified clinical trials. "Receiving orphan drug designation for the treatment of GPP is an important milestone for our wholly-owned imsidolimab program," said Hamza Suria, president and chief executive officer of AnaptysBio. "We look forward to advancing clinical development of imsidolimab in GPP, PPP and additional clinical indications that may be driven by dysregulated IL-36R signaling."...AnaptysBio is currently advancing clinical development of imsidolimab in two indications and plans to expand into additional unmet medical needs. Treatment of GPP by imsidolimab is being evaluated in the GALLOP Phase 2 trial, where additional clinical data and a regulatory update is anticipated in the second half of 2020. PPP treatment with imsidolimab is being evaluated in the randomized, placebo-controlled POPLAR Phase 2 trial where top-line data is anticipated in the second half of 2020. In addition, AnaptysBio intends to initiate Phase 2 clinical trials with imsidolimab in two additional indications, in which human translational data suggests dysregulated IL-36R signaling, during the second half of 2020.

ShowHide Related Items >><<
ANAB AnaptysBio
$22.64 /

-0.02 (-0.09%)

ANAB AnaptysBio
$22.64 /

-0.02 (-0.09%)

01/16/20 Cantor Fitzgerald
AnaptysBio risk/reward favorable into second half data, says Cantor Fitzgerald
11/11/19 SunTrust
AnaptysBio downgraded to Hold from Buy at SunTrust
11/08/19 Cantor Fitzgerald
Cantor cuts AnaptysBio target to $28 from $140, sees value in shares
11/08/19 Jefferies
AnaptysBio downgraded to Hold from Buy at Jefferies
ANAB AnaptysBio
$22.64 /

-0.02 (-0.09%)

Over a month ago
Earnings
AnaptysBio reports Q1 EPS (30c), consensus (63c) » 16:38
05/06/20
05/06
16:38
05/06/20
16:38
ANAB

AnaptysBio

$17.46 /

-0.13 (-0.74%)

Cash, cash equivalents…

Cash, cash equivalents and investments totaled $412.7 million as of March 31, 2020 compared to $428.5 million as of December 31, 2019, for a decrease of $15.8 million. The decrease relates primarily to cash used for operating activities."Our wholly-owned pipeline continues to advance with three Phase 2 clinical trial readouts anticipated in the remainder of 2020," said Hamza Suria, president and chief executive officer of AnaptysBio. "AnaptysBio's capital-efficient business model has resulted in the advancement of 7 internally-generated antibodies to the clinic to date, and we anticipate continued discovery and development of novel antibodies in the upcoming future. We also look forward to significant revenues associated with regulatory filing related milestone payment and future royalties upon FDA approval of dostarlimab under our GSK partnership later this year."

ShowHide Related Items >><<
ANAB AnaptysBio
$17.46 /

-0.13 (-0.74%)

01/16/20 Cantor Fitzgerald
AnaptysBio risk/reward favorable into second half data, says Cantor Fitzgerald
11/11/19 SunTrust
AnaptysBio downgraded to Hold from Buy at SunTrust
11/08/19 Cantor Fitzgerald
Cantor cuts AnaptysBio target to $28 from $140, sees value in shares
11/08/19 Jefferies
AnaptysBio downgraded to Hold from Buy at Jefferies
Earnings
AnaptysBio reports Q1 EPS (30c), consensus (63c) » 16:38
05/06/20
05/06
16:38
05/06/20
16:38
ANAB

AnaptysBio

$17.46 /

-0.13 (-0.74%)

Cash, cash equivalents…

Cash, cash equivalents and investments totaled $412.7 million as of March 31, 2020 compared to $428.5 million as of December 31, 2019, for a decrease of $15.8 million. The decrease relates primarily to cash used for operating activities."Our wholly-owned pipeline continues to advance with three Phase 2 clinical trial readouts anticipated in the remainder of 2020," said Hamza Suria, president and chief executive officer of AnaptysBio. "AnaptysBio's capital-efficient business model has resulted in the advancement of 7 internally-generated antibodies to the clinic to date, and we anticipate continued discovery and development of novel antibodies in the upcoming future. We also look forward to significant revenues associated with regulatory filing related milestone payment and future royalties upon FDA approval of dostarlimab under our GSK partnership later this year."

ShowHide Related Items >><<
ANAB AnaptysBio
$17.46 /

-0.13 (-0.74%)

01/16/20 Cantor Fitzgerald
AnaptysBio risk/reward favorable into second half data, says Cantor Fitzgerald
11/11/19 SunTrust
AnaptysBio downgraded to Hold from Buy at SunTrust
11/08/19 Cantor Fitzgerald
Cantor cuts AnaptysBio target to $28 from $140, sees value in shares
11/08/19 Jefferies
AnaptysBio downgraded to Hold from Buy at Jefferies
Over a quarter ago
Hot Stocks
AnaptysBio expects cash, cash quivalents to fund plan at least into 2023 » 09:12
03/02/20
03/02
09:12
03/02/20
09:12
ANAB

AnaptysBio

$14.96 /

+0.36 (+2.47%)

AnaptysBio expects its…

AnaptysBio expects its net cash burn in 2020 will be approximately $60.0 million, and that its cash, cash equivalents and investments will fund its current operating plan at least into 2023.

ShowHide Related Items >><<
ANAB AnaptysBio
$14.96 /

+0.36 (+2.47%)

01/16/20 Cantor Fitzgerald
AnaptysBio risk/reward favorable into second half data, says Cantor Fitzgerald
11/11/19 SunTrust
AnaptysBio downgraded to Hold from Buy at SunTrust
11/08/19 Cantor Fitzgerald
Cantor cuts AnaptysBio target to $28 from $140, sees value in shares
11/08/19 Jefferies
AnaptysBio downgraded to Hold from Buy at Jefferies
Hot Stocks
AnaptysBio anticipates $10M cash milestone payment on BLA filing acceptance » 09:12
03/02/20
03/02
09:12
03/02/20
09:12
GSK

GlaxoSmithKline

$40.51 /

-1.07 (-2.57%)

, ANAB

AnaptysBio

$14.96 /

+0.36 (+2.47%)

GSK has recently…

GSK has recently announced that a first BLA filing for dostarlimab, an AnaptysBio-generated PD-1 antagonist antibody under partnership with TESARO, a GSK company, occurred in the fourth quarter of 2019 for the treatment of endometrial cancer. AnaptysBio anticipates receiving a $10.0 million cash milestone payment upon acceptance of this BLA filing and a $20.0 million cash milestone upon first FDA approval of dostarlimab. Including additional cash milestones due upon future development and commercialization of dostarlimab, TSR-022, an AnaptysBio-generated TIM-3 antibody, and TSR-033, an AnaptysBio-generated LAG-3 antibody, AnaptysBio can potentially receive a total of $1.1 billion in aggregate milestone payments under this GSK partnership. In addition, AnaptysBio is due a 4% to 8% royalty from GSK, tiered upon global sales, for each of the aforementioned programs.

ShowHide Related Items >><<
GSK GlaxoSmithKline
$40.51 /

-1.07 (-2.57%)

01/16/20 Barclays
GlaxoSmithKline downgraded to Underweight from Equal Weight at Barclays
12/16/19 Goldman Sachs
BioMarin, Regeneron among Goldman's six Healthcare 'laggards' for 2020
12/03/19 Morgan Stanley
Morgan Stanley sees high odds of Bluebird trading up after multiple myeloma data
12/02/19 SVB Leerink
GlaxoSmithKline initiated with an Outperform at SVB Leerink
ANAB AnaptysBio
$14.96 /

+0.36 (+2.47%)

01/16/20 Cantor Fitzgerald
AnaptysBio risk/reward favorable into second half data, says Cantor Fitzgerald
11/11/19 SunTrust
AnaptysBio downgraded to Hold from Buy at SunTrust
11/08/19 Cantor Fitzgerald
Cantor cuts AnaptysBio target to $28 from $140, sees value in shares
11/08/19 Jefferies
AnaptysBio downgraded to Hold from Buy at Jefferies
Hot Stocks
AnaptysBio to file IND for ANB032 in 2H20 » 09:11
03/02/20
03/02
09:11
03/02/20
09:11
ANAB

AnaptysBio

$14.96 /

+0.36 (+2.47%)

The company said,…

The company said, "Our fourth wholly-owned program is an anti-BTLA modulator antibody, known as ANB032, which is broadly applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. Mutations in the BTLA signaling pathway are associated with human inflammatory disease and we believe ANB032 silences pro-inflammatory signaling by modulating BTLA binding to HVEM. We anticipate filing an IND for ANB032 in the second half of 2020."

ShowHide Related Items >><<
ANAB AnaptysBio
$14.96 /

+0.36 (+2.47%)

01/16/20 Cantor Fitzgerald
AnaptysBio risk/reward favorable into second half data, says Cantor Fitzgerald
11/11/19 SunTrust
AnaptysBio downgraded to Hold from Buy at SunTrust
11/08/19 Cantor Fitzgerald
Cantor cuts AnaptysBio target to $28 from $140, sees value in shares
11/08/19 Jefferies
AnaptysBio downgraded to Hold from Buy at Jefferies
Hot Stocks
AnaptysBio to initiate Phase 1 trial of ANB030 in 1H20 » 09:11
03/02/20
03/02
09:11
03/02/20
09:11
ANAB

AnaptysBio

$14.96 /

+0.36 (+2.47%)

ANB030 is a wholly-owned…

ANB030 is a wholly-owned antibody that binds PD-1 in an agonistic manner, leading to reduced T cell activity and anti-inflammatory effects in vivo. Genetic mutations in the PD-1 pathway are associated with increased susceptibility to various inflammatory conditions and we believe ANB030 has the potential to suppress inflammatory diseases by restoring insufficient PD-1-mediated negative signaling on activated T cells. The Company plans to focus future clinical development of ANB030 on certain autoimmune diseases where PD-1 checkpoint receptor function may be under-represented, submitted an Investigational New Drug Application in the fourth quarter of 2019 and plans to initiate a Phase 1 clinical trial in the first half of 2020. Preclinical data from the ANB030 was presented in June at the 2019 FOCIS Annual Meeting.

ShowHide Related Items >><<
ANAB AnaptysBio
$14.96 /

+0.36 (+2.47%)

01/16/20 Cantor Fitzgerald
AnaptysBio risk/reward favorable into second half data, says Cantor Fitzgerald
11/11/19 SunTrust
AnaptysBio downgraded to Hold from Buy at SunTrust
11/08/19 Cantor Fitzgerald
Cantor cuts AnaptysBio target to $28 from $140, sees value in shares
11/08/19 Jefferies
AnaptysBio downgraded to Hold from Buy at Jefferies
Hot Stocks
AnaptysBio expects topline data from POPLAR trial in 2H20 » 09:10
03/02/20
03/02
09:10
03/02/20
09:10
ANAB

AnaptysBio

$14.96 /

+0.36 (+2.47%)

In September, AnaptysBio…

In September, AnaptysBio announced positive topline data from an interim analysis of its Phase 2 clinical trial of ANB019 monotherapy in moderate-to-severe generalized pustular psoriasis, or GPP, also known as the GALLOP trial. In this interim analysis, both patients achieved the primary endpoint of disease score improvement at Day 29 and Day 113 without requiring rescue therapy, demonstrated rapid and sustained mJDA score improvement, with reduction of 58% at Day 8 and 63% at Day 113, and showed complete clearance of skin pustules by Day 8 and through Day 113, with CRP levels decreasing to nearly normal. Enrollment is ongoing in the GALLOP study, and the Company anticipates additional clinical data and a regulatory strategy update for the development of ANB019 in GPP during 2020. The Company is also conducting a randomized, placebo-controlled, multi-dose Phase 2 trial in 50 patients with palmoplantar pustulosis, or PPP, also known as the POPLAR trial, with topline data anticipated in the second half of 2020. AnaptysBio has taken steps to enhance enrollment in the GALLOP and POPLAR trials, including expansion of clinical trial sites and countries.

ShowHide Related Items >><<
ANAB AnaptysBio
$14.96 /

+0.36 (+2.47%)

01/16/20 Cantor Fitzgerald
AnaptysBio risk/reward favorable into second half data, says Cantor Fitzgerald
11/11/19 SunTrust
AnaptysBio downgraded to Hold from Buy at SunTrust
11/08/19 Cantor Fitzgerald
Cantor cuts AnaptysBio target to $28 from $140, sees value in shares
11/08/19 Jefferies
AnaptysBio downgraded to Hold from Buy at Jefferies
Hot Stocks
AnaptysBio decides to postpone initiation of Phase 2b etokimab trial » 09:10
03/02/20
03/02
09:10
03/02/20
09:10
ANAB

AnaptysBio

$14.96 /

+0.36 (+2.47%)

AnaptysBio is conducting…

AnaptysBio is conducting a randomized, placebo-controlled Phase 2 trial in approximately 100 adult patients with chronic rhinosinusitis with nasal polyps, also referred to as the ECLIPSE trial. Patients are being treated with two multi-dosing frequencies of subcutaneously-administered etokimab or placebo, each in combination with mometasone furoate nasal spray as background therapy. The Company anticipates topline data from an interim analysis of the ECLIPSE trial in the first half of 2020. The Company previously announced data from its ATLAS trial, a Phase 2b randomized, double-blinded, placebo-controlled, multi-dose study in approximately 300 adult patients treated with etokimab in moderate-to-severe atopic dermatitis. Each of the etokimab dosing arms failed to meet the primary endpoint of the trial, which was demonstration of statistically greater improvement in the Eczema Area and Severity Index relative placebo at week 16. AnaptysBio has discontinued development of etokimab in moderate-to-severe atopic dermatitis. The Company has decided to postpone the initiation of its planned Phase 2b etokimab clinical trial in eosinophilic asthma, a multi-dose, randomized, double-blinded, placebo-controlled trial in 300-400 patients, until results are available from the ECLIPSE trial.

ShowHide Related Items >><<
ANAB AnaptysBio
$14.96 /

+0.36 (+2.47%)

01/16/20 Cantor Fitzgerald
AnaptysBio risk/reward favorable into second half data, says Cantor Fitzgerald
11/11/19 SunTrust
AnaptysBio downgraded to Hold from Buy at SunTrust
11/08/19 Cantor Fitzgerald
Cantor cuts AnaptysBio target to $28 from $140, sees value in shares
11/08/19 Jefferies
AnaptysBio downgraded to Hold from Buy at Jefferies

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.